ArcticZymes Technologies presents at Redeye R&D Tools Seminar

Attached is a copy of the presentation held by CEO Jethro Holter at the Redeye R&D Tools Seminar in Stockholm, 10 November 2020.

The presentation will also be available on the web-site www.arcticzymes.com
 

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company with a core strategic focus on specialized and novel enzyme technologies.

The ArcticZymes Group is creating value from innovation in life science markets via its subsidiaries, ArcticZymes and Biotec BetaGlucans. Its technologies capitalize on more than three decades of world-class research at the Arctic University of Tromsø to offer niche and high-tech products in several biotech segments.

ArcticZymes represents the company’s core business. It develops, manufactures and commercialises novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Biotec BetaGlucans represents a non-core business focusing on the marketing of immunomodulating beta-glucans in several market segments.

Listed on the Oslo Stock Exchange since 2005, earlier under the [Biotec] ticker and since June 2020 under the new [AZT] ticker. ArcticZymes Technologies headquarters is located in Tromsø, Norway, in the SIVA Innovation Centre.

ArcticZymes Technologies’ unique IP and capabilities are protected via a large portfolio of patents around both enzyme and beta-glucan products.

For more information, please visit the website: www.arcticzymes.com